LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the completion of its previously announced underwritten public offering of 3,300,000 shares of its common stock. All shares in the offering were sold by Concert at a public offering price of $15.15 per share. Net proceeds to Concert are expected to be approximately $46.7 million, after deducting underwriting discounts and commissions and estimated offering expenses and not including any proceeds to be received by Concert if the underwriters exercise their 30-day option to purchase up to an additional 495,000 shares of our common stock.
Help employers find you! Check out all the jobs and post your resume.
